Journavx (suzetrigine) — Coverage Criteria
Customize your policy alerts
Sign up for all Neighborhood Health Plan of Rhode Island policy alerts
Know when Neighborhood Health Plan of Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization and coverage criteria for the prescription drug Journavx (suzetrigine) for members of Neighborhood Health Plan of Rhode Island aged 18 and older.
No material clinical or coverage changes in this revision.
Coverage Criteria for Journavx (suzetrigine)
Initial Therapy
Covered when ALL of the following are met:
Neighborhood does not provide coverage for drugs when used for investigational purposes or at doses or for conditions that are not recognized as medically accepted indications per standard compendia. Therapies are considered investigational when used outside of compendium‑supported indications or dosing; such uses are excluded from coverage.
Use of Journavx for investigational indications or at non‑compendium‑supported doses is considered not medically necessary and will not be covered.
Initial Authorization Requirements
Initial Therapy — detailed initial authorization requirements
Initial authorization requirements
Continuation and Refill Rules
Continuation / Refill rules
Coverage duration and refill timing
Provider Requirements and Prior Authorization
Prior Authorization Required
Prior authorization required. Document that the patient is age 18 or older, has moderate to severe pain, and has had a trial and failure of at least one generic analgesic (e.g., NSAID, acetaminophen, opioid) within the prior 30 days, or documentation that alternatives are inappropriate; OR documents history of opioid use disorder. Also document that Journavx will not be taken concomitantly with a CYP3A4 inhibitor (e.g., clarithromycin, itraconazole, ritonavir, ketoconazole, nefazodone, voriconazole).
- Coverage duration: 6 weeks
- Quantity limit: Journavx 50 mg — 29 tablets per 14-day supply every 6 weeks (additional fill only after 6 weeks since initial fill)
Step Therapy Requirement
Step therapy applies. A trial and documented failure of at least one generic analgesic agent within the prior 30 days is required before coverage of Journavx is approved. Alternatively, there must be documentation that alternative medications are not appropriate. For members with opioid use disorder, documentation of a qualifying buprenorphine product claim (e.g., buprenorphine SL tablets, buprenorphine/naloxone SL tablets or films, Brixadi, Sublocade) may satisfy step-therapy logic.
- Step requirement: trial and failure of ≥1 generic analgesic within 30 days
- Acceptable alternatives: NSAIDs, acetaminophen, opioids (with documented trial/failure)
- Step override: documented contraindication or history of opioid use disorder with evidence of buprenorphine treatment claim
Required Documentation
Required documentation must be submitted with the authorization request: patient age (≥18), objective or clinician-documented moderate to severe pain, evidence of trial and failure of ≥1 generic medication (or documentation why alternatives are inappropriate), any history of opioid use disorder, and verification that the member will not use Journavx with CYP3A4 inhibitors.
- Document age ≥18
- Document pain severity (moderate to severe)
- Document trial and failure of ≥1 generic analgesic or rationale for inappropriateness
- Document history of opioid use disorder when applicable
- Document absence of concomitant CYP3A4 inhibitor therapy (list examples)
Triggers for Denial
Denial may be issued if required criteria or documentation are missing. Common triggers for denial include: patient under 18, lack of documentation of moderate to severe pain, no evidence of trial and failure of a generic analgesic (or lack of documented rationale), concurrent use of a CYP3A4 inhibitor, or use for investigational/unapproved indications.
- Underage (<18)
- No documentation of pain severity
- No documentation of prior trial and failure of ≥1 generic medication within prior 30 days (or inadequate rationale)
- Concomitant CYP3A4 inhibitor use
- Requesting use for investigational indication
Step Therapy Logic
| Step | Requirement | Coverage/payment logic |
|---|---|---|
| 1 | ||
| Trial and failure of ≥1 generic analgesic (NSAID, acetaminophen, or opioid) within the previous 30 days — OR documentation that alternatives are not appropriate; alternative pathway: history of opioid use disorder | ||
| Covered if prior trial/failure criteria met. Additionally, coding logic allows payment if there is at least one paid claim for a buprenorphine product for dependence (e.g., buprenorphine SL tablets, buprenorphine/naloxone, Brixadi, or Sublocade). |
Coding and Age Constraints
| No codes listed |
Quantity Limits and Dispensing
Definitions and Drug Interaction Examples
Background
Journavx (suzetrigine) is a prescription analgesic indicated for patients with moderate to severe pain. Coverage under this policy is limited to members who are 18 years of age or older and who meet the prior authorization criteria, including documentation of pain severity, required prior trials or acceptable exceptions, and avoidance of concomitant use with CYP3A4 inhibitors (examples listed: clarithromycin, itraconazole, ritonavir, ketoconazole, nefazodone, voriconazole).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.